References

Disease burden and long-term trends of urinary tract infections: A worldwide report

10.3389/fpubh.2022.888205 · 2022 · External reference

Urinary tract infections: epidemiology, mechanisms of infection and treatment options

10.1038/nrmicro3432 · 2015 · External reference

Recurrent urinary tract infections in women

10.1007/s00192-014-2569-5 · 2015 · External reference

Recurrent urinary tract infections

2026 · External reference

Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions

10.1093/jac/dkx504 · 2018 · External reference

An introduction to the epidemiology and burden of urinary tract infections

10.1177/1756287219832172 · 2019 · External reference

Update on urinary tract infection antibiotic resistance - A retrospective study in females in conjunction with clinical data

10.3390/life14010106 · 2024 · External reference

Epidemiology and microbiology of recurrent UTI in women in the community in Oxfordshire, UK

10.1093/jacamr/dlad156 · 2024 · External reference

The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline

10.1016/s2666-5247(22)00303-2 · 2023 · External reference

A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections

10.1016/j.eururo.2004.12.009 · 2005 · External reference

MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88

10.1038/mi.2016.112 · 2017 · External reference

Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study

10.1007/s11255-021-02987-4 · 2021 · External reference

Role of vaccines for recurrent urinary tract infections: a systematic review

10.1016/j.euf.2019.11.002 · 2020 · External reference

Unresolved reference

External reference

The clinical progress of mRNA vaccines and immunotherapies

10.1038/s41587-022-01294-2 · 2022 · External reference

Challenges and opportunities in mRNA vaccine development against bacteria

10.1038/s41564-025-02070-z · 2025 · External reference

mRNA vaccine platforms to prevent bacterial infections

10.1016/j.molmed.2024.02.013 · 2024 · External reference

The remarkable biomechanical properties of the type 1 chaperone-usher pilus: A structural and molecular perspective

10.1128/microbiolspec.psib-0010-2018 · 2019 · External reference

Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding

10.1073/pnas.0902179106 · 2009 · External reference

Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation

10.1073/pnas.1315203110 · 2013 · External reference

Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI

10.1126/sciadv.adw0698 · 2025 · External reference

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

10.1038/nature22972 · 2017 · External reference

Antivirulence C-mannosides as antibiotic-sparing, oral therapeutics for urinary tract infections

10.1021/acs.jmedchem.6b00948 · 2016 · External reference

Treatment and prevention of urinary tract infection with orally active FimH inhibitors

10.1126/scitranslmed.3003021 · 2011 · External reference

An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodents

10.3389/fimmu.2025.1668937 · 2025 · External reference

Self-assembled ferritin nanoparticles for delivery of antigens and development of vaccines: from structure and property to applications

10.3390/molecules29174221 · 2024 · External reference

Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection

10.1128/iai.69.7.4572-4579.2001 · 2001 · External reference

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

10.1038/nature12202 · 2013 · External reference

Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection

10.1371/journal.ppat.1004599 · 2015 · External reference

A murine model of urinary tract infection

10.1038/nprot.2009.116 · 2009 · External reference

inventors

2015 · External reference

Mucosal infection rewires TNFɑ signaling dynamics to skew susceptibility to recurrence

10.7554/elife.46677 · 2019 · External reference

Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli

10.1128/iai.54.3.613-620.1986 · 1986 · External reference

Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli isolate

10.1128/iai.33.3.933-938.1981 · 1981 · External reference

Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains

10.1128/iai.58.5.1281-1289.1990 · 1990 · External reference

Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated st131 lineage: genome analysis and virulence mechanisms

10.1371/journal.pone.0026578 · 2011 · External reference

Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection

10.1371/journal.ppat.1001042 · 2010 · External reference

Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis

10.1016/j.ebiom.2014.10.011 · 2014 · External reference

A mucosal imprint left by prior Escherichia coli bladder infection sensitizes to recurrent disease

10.1038/nmicrobiol.2016.196 · 2016 · External reference

Microbial threshold guidelines for UTI diagnosis: A scoping systematic review

10.2147/plmi.s409488 · 2023 · External reference

A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates

10.1128/iai.00169-24 · 2024 · External reference

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination

10.1126/science.276.5312.607 · 1997 · External reference

Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study

10.1080/21645515.2020.1834807 · 2021 · External reference

A guide to vaccinology: from basic principles to new developments

10.1038/s41577-020-00479-7 · 2021 · External reference

Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine

10.1371/journal.ppat.1012325 · 2025 · External reference

Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine

10.1586/erv.12.36 · 2012 · External reference

Mucosal immunization with iron receptor antigens protects against urinary tract infection

10.1371/journal.ppat.1000586 · 2009 · External reference

G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity

10.1111/j.1462-5822.2008.01230.x · 2008 · External reference

Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuria

10.1080/02813430902757634 · 2009 · External reference

Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections

10.1080/21645515.2020.1770034 · 2021 · External reference

FimH and anti-adhesive therapeutics: a disarming strategy against uropathogens

10.3390/antibiotics9070397 · 2020 · External reference

Distribution of phylogenetic groups, adhesin genes, biofilm formation, and antimicrobial resistance of uropathogenic Escherichia coli isolated from hospitalized patients in Thailand

10.7717/peerj.10453 · 2020 · External reference

Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection

10.1046/j.1365-2958.2002.02915.x · 2002 · External reference

Decreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli reduces urinary tract infection

10.1128/iai.00162-12 · 2012 · External reference

Ferritin-based HA DNA vaccine outperforms conventional designs in inducing protective immunity against seasonal influenza

10.3390/vaccines13070745 · 2025 · External reference

SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses

10.1038/s41541-021-00414-4 · 2021 · External reference

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies

10.1586/14760584.2016.1129905 · 2016 · External reference

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

10.1126/scitranslmed.ade4790 · 2023 · External reference

182. Progress towards an EBV vaccine: results of a phase i, first-in-human EBV gp350 ferritin nanoparticle vaccine candidate adjuvanted with Matrix-M®

10.1093/ofid/ofaf695.061 · 2026 · External reference

Current scientific advances in vaccines against UTIs: challenges and prospects

10.3390/microorganisms13122714 · 2025 · External reference